冠状动脉血运重建后P2Y12抑制剂单药治疗与双联抗血小板治疗的比较:随机对照试验的个体患者水平荟萃分析
该个体患者水平荟萃分析纳入6项随机对照试验共24 096例冠状动脉血运重建后无口服抗凝指征的患者,比较P2Y12抑制剂单药与DAPT。主要复合终点(全因死亡、心肌梗死、卒中)在符合方案人群中单药组2.95% vs DAPT组3.27%(HR 0.93,95%CI 0.79-1.09;非劣效性P=0.005;优效性P=0.38),意向治疗人群2.94% vs 3.36%(HR 0.90,95%CI 0.77-1.05;优效性P=0.18)。BARC 3或5型出血单药组0.89% vs DAPT组1.83%(HR 0.49,95%CI 0.39-0.63;P<0.001)。结论提示单药治疗缺血风险相似且出血更少,但性别交互作用提示女性可能获益更多。
要点
- 在24 096例血运重建后无口服抗凝指征患者中,P2Y12抑制剂单药较DAPT主要缺血终点非劣效(符合方案人群HR 0.93,95%CI 0.79-1.09;非劣效性P=0.005)。
- 单药治疗BARC 3或5型出血风险显著低于DAPT(0.89% vs 1.83%;HR 0.49,95%CI 0.39-0.63;P<0.001)。
- 性别交互作用显著(交互P=0.02):女性单药主要缺血终点HR 0.64(95%CI 0.46-0.89),男性HR 1.00(95%CI 0.83-1.19)。
- P2Y12抑制剂类型交互作用显著(交互P=0.02),提示DAPT方案中含较新型P2Y12抑制剂而非氯吡格雷时单药获益更大。
- 意向治疗人群主要终点单药2.94% vs DAPT 3.36%(HR 0.90,95%CI 0.77-1.05;优效性P=0.18),未达统计学显著。
适用人群与场景
- 冠状动脉血运重建后无口服抗凝指征的患者,纳入6项随机对照试验共24 096例。
诊断标准与关键阈值
- 主要终点为非劣效性检验,非劣效界值为风险比1.15。
研究设计与关键结果
- 研究类型为随机对照试验的个体患者水平荟萃分析,纳入6项试验共24 096例患者,比较口服P2Y12抑制剂单药与DAPT。
- 主要复合终点(全因死亡、心肌梗死、卒中)在符合方案人群中单药组283例(2.95%)vs DAPT组315例(3.27%),HR 0.93(95%CI 0.79-1.09),非劣效性P=0.005,优效性P=0.38,τ²=0.00。
- 主要复合终点在意向治疗人群中单药组303例(2.94%)vs DAPT组338例(3.36%),HR 0.90(95%CI 0.77-1.05),优效性P=0.18,τ²=0.00。
- 治疗效应在所有亚组中一致,除性别外(交互P=0.02):女性单药主要缺血终点HR 0.64(95%CI 0.46-0.89),男性HR 1.00(95%CI 0.83-1.19)。
- BARC 3或5型出血单药组97例(0.89%)vs DAPT组197例(1.83%),HR 0.49(95%CI 0.39-0.63),P<0.001,τ²=0.03;除P2Y12抑制剂类型外(交互P=0.02),各亚组一致,提示DAPT方案中含较新型P2Y12抑制剂而非氯吡格雷时单药获益更大。
证据类型、等级与局限
- 证据类型为随机对照试验的个体患者水平荟萃分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于冠状动脉血运重建后无口服抗凝指征的患者,P2Y12抑制剂单药治疗与DAPT相比死亡、心肌梗死或卒中风险相似,且出血风险更低;治疗效应可能受性别和DAPT中P2Y12抑制剂类型影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the risks and benefits of P2Y12 inhibitor monotherapy compared with dual antiplatelet therapy (DAPT) and whether these associations are modified by patients' characteristics.
DESIGN: Individual patient level meta-analysis of randomised controlled trials.
DATA SOURCES: Searches were conducted in Ovid Medline, Embase, and three websites (www.tctmd.com, www.escardio.org, www.acc.org/cardiosourceplus) from inception to 16 July 2020. The primary authors provided individual participant data.
ELIGIBILITY CRITERIA: Randomised controlled trials comparing effects of oral P2Y12 monotherapy and DAPT on centrally adjudicated endpoints after coronary revascularisation in patients without an indication for oral anticoagulation.
MAIN OUTCOME MEASURES: The primary outcome was a composite of all cause death, myocardial infarction, and stroke, tested for non-inferiority against a margin of 1.15 for the hazard ratio. The key safety endpoint was Bleeding Academic Research Consortium (BARC) type 3 or type 5 bleeding.
RESULTS: The meta-analysis included data from six trials, including 24 096 patients. The primary outcome occurred in 283 (2.95%) patients with P2Y12 inhibitor monotherapy and 315 (3.27%) with DAPT in the per protocol population (hazard ratio 0.93, 95% confidence interval 0.79 to 1.09; P=0.005 for non-inferiority; P=0.38 for superiority; τ2=0.00) and in 303 (2.94%) with P2Y12 inhibitor monotherapy and 338 (3.36%) with DAPT in the intention to treat population (0.90, 0.77 to 1.05; P=0.18 for superiority; τ2=0.00). The treatment effect was consistent across all subgroups, except for sex (P for interaction=0.02), suggesting that P2Y12 inhibitor monotherapy lowers the risk of the primary ischaemic endpoint in women (hazard ratio 0.64, 0.46 to 0.89) but not in men (1.00, 0.83 to 1.19). The risk of bleeding was lower with P2Y12 inhibitor monotherapy than with DAPT (97 (0.89%) v 197 (1.83%); hazard ratio 0.49, 0.39 to 0.63; P<0.001; τ2=0.03), which was consistent across subgroups, except for type of P2Y12 inhibitor (P for interaction=0.02), suggesting greater benefit when a newer P2Y12 inhibitor rather than clopidogrel was part of the DAPT regimen.
CONCLUSIONS: P2Y12 inhibitor monotherapy was associated with a similar risk of death, myocardial infarction, or stroke, with evidence that this association may be modified by sex, and a lower bleeding risk compared with DAPT.
REGISTRATION: PROSPERO CRD42020176853.
参考来源
- Valgimigli M, Gragnano F, Branca M, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ. 2021. PMID: 34135011. doi:10.1136/bmj.n1332
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。